Timothy Wollaeger
Managing Director @ Sanderling Ventures
Greater San Diego Area, United States
Timothy Wollaeger is a Series B investor at Sanderling Ventures in Greater San Diego Area focused on Health Care and Information Technology. Tim has nearly thirty years' experience in the medical products and biotechnology fields in both corporate management and venture capital. Mr. Wollaeger joined Sanderling as a Managing Director in 2002, as head of the firm's San Diego office.Mr. Wollaeger began his career at Baxter International where his last position was VicePresident and General Manager of the Company's operations in Mexico. In 1983 he joined Hybritech, Inc., San Diego's first biotechnology company, as Vice President and Chief Financial Officer. Following Hybritech's acquisition by Eli Lilly & Co in 1986, he became a founding General Partner of Biovest, a San Diego based venture capital firm. At Biovest, he helped found and remained an active Board member in Pyxis, Vical and Biosite. All three of these companies became public and Pyxis was acquired by Cardinal Health in 1996 for a $1 billion.He then helped found Columbia Hospital Corporation in 1990 and was a Senior Vice President and member of the Board of Directors until 1994, when he left to found the venture capital firm Kingsbury Capital Partners. Kingbury's investments include Aurora Biosciences, Amylin Pharmaceuticals, Phamis Software, Health Data Sciences, Senomyx, Sub-Q, TKT, Althea, and Digirad.In San Diego, he was named Entrepreneur of the Year in 1995 and Corporate Director of the Year in 2001. Mr. Wollaeger earned a B.A. in Economics from Yale in 1966, served as an officer in the U.S. Navy for three years, and earned an MBA from The Stanford Graduate School of Business in 1971.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 18%
Last updated:
For AI agents: llms.txt
Industries Timothy Wollaeger invests in
Stages Timothy Wollaeger invests in
Countries Timothy Wollaeger invests in
Investment Focus
Industry
- Health Care 3 (27%)
- Information Technology 3 (27%)
- Medical 1 (9%)
- Hospital 1 (9%)
- Life Science 1 (9%)
Stage
- Series B 2 (18%)
- Series C 2 (18%)
- Funding Round 2 (18%)
- Series D 1 (9%)
- Post-IPO Equity 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
CalciMedica
|
CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $55M / Post-IPO Equity / Jan 22, 2024 | |
|
CalciMedica
|
CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $21M / Series D / Mar 11, 2021 | |
|
CalciMedica
|
CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $15M / Series C / May 22, 2020 | |
|
CalciMedica
|
CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $4M / Series C / Jan 04, 2009 | |
|
CalciMedica
|
CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $5.5M / Series B / Feb 13, 2008 | |
Asteres
|
Asteres Inc., founded in 2003, is a prescription and pharmacy automation technology group. They were the first company to commercialize a system to store and deliver finished prescriptions to consumers in retail pharmacy. ScriptCenter, which works like an ATM, allows consumers to pickup and pay for their prescriptions when the pharmacy is closed*or without waiting in line when the pharmacy is open. Retailers can extend prescription pickup hours without adding staff and also alleviate the stress of long lines at the pharmacy counter. Retailers particularly appreciate that ScriptCenter convenience brings consumers in the store and keeps them shopping unlike drive-thru or home delivery. The Asteres management team has extensive experience in healthcare automation in hospital & healthcare systems and retail pharmacy. The team is known for successfully growing technology companies that have intense focus on customer value and customer service. | $4M / Series C / Nov 01, 2007 | |
Alteer
|
Alteer optimizes overall performance of medical practices of any size. Alteer’s Internet based software is the only integrated platform that eliminates paper completely and automates the entire workflow in a physician’s practice - from scheduling to charting to billing and patient messaging. | $9.4M / Oct 11, 2002 | |
|
CalciMedica
|
CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $12M / Series C | |
|
Alteer
|
Alteer optimizes overall performance of medical practices of any size. Alteer’s Internet based software is the only integrated platform that eliminates paper completely and automates the entire workflow in a physician’s practice - from scheduling to charting to billing and patient messaging. | $16.5M | |
|
Asteres
|
Asteres Inc., founded in 2003, is a prescription and pharmacy automation technology group. They were the first company to commercialize a system to store and deliver finished prescriptions to consumers in retail pharmacy. ScriptCenter, which works like an ATM, allows consumers to pickup and pay for their prescriptions when the pharmacy is closed*or without waiting in line when the pharmacy is open. Retailers can extend prescription pickup hours without adding staff and also alleviate the stress of long lines at the pharmacy counter. Retailers particularly appreciate that ScriptCenter convenience brings consumers in the store and keeps them shopping unlike drive-thru or home delivery. The Asteres management team has extensive experience in healthcare automation in hospital & healthcare systems and retail pharmacy. The team is known for successfully growing technology companies that have intense focus on customer value and customer service. | Series B | |
| See all 11 investments → | |||
Co-Investors
Bering Capital
2 deals together
Quark Venture
2 deals together
SR One
2 deals together
Valence Life Sciences
2 deals together
Aisling Capital
1 deal together
Biogen
1 deal together
About Sanderling Ventures
Sanderling Ventures is an investment company that specializes in seed and early-stage investments. It also participates in later-stage financings. The firm focuses on new biomedical market opportunities, including emerging technology in the areas such as biotechnology, life sciences, therapeutics and pharmaceuticals, drug delivery, medical devices,and instrumentation; imaging and diagnostics, medical informatics, healthcare information technology; and health care services. It seeks to invest in United States and Canada.Sanderling Ventures was founded by Robert McNeil in 1979 and is headquartered in Sam Mateo, California.
Sanderling Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Fred Middleton
Managing Director
|
|||
Timothy C. Mills
Managing Director
|
|||
|
Timothy Wollaeger
Managing Director
|
|||
Michael Dixon
Managing Director
|
|||
Paulette Taylor
General Counsel & Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Timothy Wollaeger invest in?
Timothy Wollaeger invests primarily in Health Care, Information Technology and Medical startups, most often at Series B and Series C stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Timothy Wollaeger last invest?
The most recent investment recorded for Timothy Wollaeger closed in Jan 2024. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
